NanoString Licenses Bioclassifier Technology | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – NanoString Technologies said late on Monday it has licensed worldwide rights to Bioclassifier technology to develop in vitro diagnostic and research products for breast cancer intrinsic subtyping.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.